ISSN 2564-7784 | E-ISSN 2564-7040
Original Article
Effects of Dapagliflozin on serum LDL-cholesterol and triglyceride levels
1 Department of Endocrinology and Metabolism, School of Medicine, University of Mustafa Kemal, Hatay, Turkey  
Eur J Ther ; : -
DOI: 10.5152/EurJTher.2019.19005
Key Words: Dapagliflozin, cardiovascular diseases, hyperlipidemia, SGLT2 inhibitor

Objective: To assess the effects of dapagliflozin, a sodium-glucose transporter2 (SGLT2) inhibitor, on serum triglyceride and LDL-cholesterol levels in type 2 diabetes mellitus patients.


Materials and methods: Forty patients with type 2 DM regularly followed-up in the Endocrinology and Metabolism Outpatient Clinic of State Hospital were retrospectively evaluated. These were the patients who were added dapagliflozin to their treatment for glycemic regulation. The patients’ anthropometric measurements, glycemic regulation status, and serum LDL-cholesterol and triglyceride levels were retrieved from the system records. Statistical analysis of drug effect was performed using repeated measures ANCOVA test keeping the effects of HbA1c and body mass index (BMI) covariates constant.


Results: In addition to the improvement in fasting blood glucose levels, HbA1c, and body weight of the patients, a reduction by 10 mg/dL and a reduction by 43.04 mg/dL were observed in serum LDL-cholesterol and triglyceride levels, respectively. The evaluation of BMI and HbA1c covariates togetherrevealed a statistically significant reduction in triglyceride levels (p=0.032 and p=0.008, respectively).


Conclusion: Besides glycemic regulation and weight loss, addition of dapagliflozin in the treatment of patients with type 2 DM is associated with an improvement in serum triglyceride levels. This result suggests thattogether with other benefits, SGLT2 inhibitors appear to provide additional benefit of reducing the risk of cardiovascular diseases.

Key Words
AVES | Copyright © 2019 European Journal of Therapeutics | Latest Update: 18.09.2019